Search Results - "el Jarari, L"

A gene expression signature for high-risk multiple myeloma by Kuiper, R, Broyl, A, de Knegt, Y, van Vliet, M H, van Beers, E H, van der Holt, B, el Jarari, L, Mulligan, G, Gregory, W, Morgan, G, Goldschmidt, H, Lokhorst, H M, van Duin, M, Sonneveld, P

“…There is a strong need to better predict the survival of patients with newly diagnosed multiple myeloma (MM). As gene expression profiles (GEPs) reflect the…”
Get full text

MicroRNA signatures characterize multiple myeloma patients by Corthals, S L, Sun, S M, Kuiper, R, de Knegt, Y, Broyl, A, van der Holt, B, Beverloo, H B, Peeters, J K, el Jarari, L, Lokhorst, H M, Zweegman, S, Jongen-Lavrencic, M, Sonneveld, P

Get full text

A gene expression signature for high-risk multiple myeloma by Kuiper, R, Broyl, A, de Knegt, Y, van Vliet, M H, van Beers, E H, van der Holt, B, el Jarari, L, Mulligan, G, Gregory, W, Morgan, G, Goldschmidt, H, Lokhorst, H M, van Duin, M, Sonneveld, P

Get full text

Erratum: A gene expression signature for high-risk multiple myeloma by Kuiper, R, Broyl, A, de Knegt, Y, van Vliet, M H, van Beers, E H, van der Holt, B, el Jarari, L, Mulligan, G, Gregory, W, Morgan, G, Goldschmidt, H, Lokhorst, H M, van Duin, M, Sonneveld, P

“…Correction to: Leukemia (2012) 26, 2406–2413; doi:10.1038/leu.2012.127 Since the publication of this article, the authors have discovered an error in the…”
Get full text

Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients by Cerrato, C, Gay, F, Petrucci, M.T, Pellegrino, M, Gaidano, G, Offidani, M, el Jarari, L, Gugielmelli, T, Salvini, M, Patriarca, F, Semenzato, G, Zweegman, S, Di Raimondo, F, Mina, R, Cascavilla, N, Yehuda, D.B, Gambella, M, Corradini, P, Lokhorst, H, Catalano, L, Di Bartolomeo, P, Hajek, R, Spencer, A, Boccadoro, M, Sonneveld, P, Palumbo, A

Get full text

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM) by Sonneveld, P., van der Holt, B., Schmidt-Wolf, I.G.H., Bertsch, U., Jarari, L. el, Salwender, Hans-Jürgen, Zweegman, S., Vellenga, E., Schubert, J., Blau, I.W., Jie, GSK, Beverloo, B., Jauch, A., Hose, D., Schaafsma, R., Kersten, M.J., Delforge, M., de Weerdt, O., van der Griend, R., Wijermans, P.W., Martin, Hans, van der Velde, H., Lokhorst, Henk M., Goldschmidt, H.

“…The randomized, open-label, phase III trial HOVON-65/GMMG-HD4 was designed to evaluate the efficacy of bortezomib prior to HDM for response and…”
Get full text

Endemic goiter in Morocco (Skoura-Toundoute areas in the High Atlas) by AQUARON, R, ZARROUCK, K, EL JARARI, M, ABABOU, R, TALIBI, A, ARDISSONE, J. P

“…Endemic goiter in Morocco is localized in the Rif and Atlas mountains. In this study, performed in the Skoura-Toundoute areas (high Atlas), we demonstrate that…”
Get full text